Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms

Next Previous
Trial Profile

A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JNJ-88549968 (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis
  • Focus Adverse reactions; First in man
  • Sponsors Janssen Research & Development

Most Recent Events

  • 22 Jun 2025 Planned End Date changed from 3 Sep 2026 to 4 Dec 2026.
  • 22 Jun 2025 Planned primary completion date changed from 1 Oct 2025 to 4 Dec 2026.
  • 28 Feb 2025 Planned End Date changed from 4 Jun 2026 to 3 Sep 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top